Sign In
29 Sep 2011 07:00
29 September 2011
Cyprotex PLC
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that Douglas Bates is stepping down from the board with effect from 28th September 2011. He will continue to serve the Company as a consultant. Mr Bates has served on the board since the Company's 2010 acquisition of Apredica, which Mr. Bates co-founded.
Mr Bates said: "It has been a privilege and an honour to take Apredica from conception to being successfully integrated with Cyprotex. Now that this is complete, I have decided to redirect my attention towards starting a new venture."
The board thanks Mr. Bates for his continuing service and wishes him well in his new venture.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | ir@cyprotex.com www.cyprotex.com |
Singer Capital Markets Limited (broker to Cyprotex) | Tel: +44 (0) 203 205 7500 |
Shaun Dobson Claes Spang
| shaun.dobson@singercm.com claes.spang@singercm.com www.singercm.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Ben Brewerton Ben Atwell Mo Noonan | cyprotex@fticonsulting.com www.fticonsulting.com
|
Notes to Editors:
Cyprotex PLC
Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.
Follow the stocks
